Key result
Rare FNIP1-disrupting variants linked to ~60% lower cardiometabolic disease risk.
Why the study?
Do rare genetic variants disrupting the FNIP1 gene improve metabolic profile and reduce the risk of cardiometabolic disease?
Observational (n=1,000,000)
Do rare genetic variants disrupting the FNIP1 gene improve metabolic profile and reduce the risk of cardiometabolic disease?
Disruption of the FNIP1 gene is associated with a highly favorable metabolic profile and a significantly lower risk of cardiometabolic disease, highlighting a potential novel therapeutic target.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“The analytical framework is robust and substantially increases the number of genes implicated in the TG/HDL ratio, a proxy for human energy metabolism. In particular, the identification of FNIP1, a previously poorly characterized gene in lipid metabolism, is highly novel and promising for future drug development for metabolic health.”
“Our focus on FNIP1 stems from the novel association of pLOF mutations in this gene with favorable metabolism and protection against cardiometabolic disease. A liver-directed therapeutic approach using GalNAc-conjugated siRNA would be expected to mitigate safety concerns associated with systemic inhibition as these agents specifically silence their targets in hepatocytes and not in other cell types.”
Does not support clinical screening or intervention; leaves open FNIP1 pathway as a therapeutic target for validation.
A study of more than one million people shows that rare genetic variants that disrupt the FNIP1 gene are associated with a favourable metabolic profile and a roughly 60% lower risk of cardiometabolic disease than the general population. Silencing genes in the FNIP1 pathway in mice induces fat breakdown and reproduces the metabolic benefits associated with the variants in humans. People with ultra-rare variants of the FNIP1 gene have a favourable metabolic profile.
No takes yet. Share an insight, caveat, or question.
A 2026 study conducted an observational in Cardiometabolic disease (n=1,000,000). Rare genetic variants disrupting the FNIP1 gene vs. General population was evaluated on Cardiometabolic disease (60% lower risk). Rare genetic variants that disrupt the FNIP1 gene are associated with a roughly 60% lower risk of cardiometabolic disease compared to the general population.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: